Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ.

Cancer Res. 2010 Sep 15;70(18):7325-35. doi: 10.1158/0008-5472.CAN-10-0607. Epub 2010 Aug 31.

2.

p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.

Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD.

J Biol Chem. 1996 Oct 11;271(41):25198-203.

3.

The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.

Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD.

Leukemia. 1997 Mar;11(3):376-85.

PMID:
9067577
4.

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.

Oncogene. 1996 Feb 15;12(4):839-46.

PMID:
8632906
5.
6.

CRKL binding to BCR-ABL and BCR-ABL transformation.

Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ.

Leuk Lymphoma. 1999 Mar;33(1-2):119-26.

PMID:
10194128
7.

Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.

Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ.

Blood. 1997 Jan 1;89(1):297-306.

8.
9.

PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST.

J Biol Chem. 2009 Jan 2;284(1):455-64. doi: 10.1074/jbc.M802840200. Epub 2008 Nov 7.

10.

A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ.

PLoS One. 2009 Oct 13;4(10):e7439. doi: 10.1371/journal.pone.0007439.

11.

Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.

Patel H, Marley SB, Greener L, Gordon MY.

Leukemia. 2008 Mar;22(3):559-71. Epub 2007 Dec 6.

PMID:
18059481
12.

Tyrosine phosphorylation of murine Crkl.

de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J.

Oncogene. 1995 Oct 19;11(8):1469-74.

PMID:
7478571
13.

CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.

Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, et al.

J Biol Chem. 1995 Dec 8;270(49):29145-50.

14.

Cellular interactions of CRKL, and SH2-SH3 adaptor protein.

ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J.

Cancer Res. 1994 May 15;54(10):2563-7.

15.

Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

Lidonnici MR, Corradini F, Waldron T, Bender TP, Calabretta B.

Blood. 2008 May 1;111(9):4771-9. doi: 10.1182/blood-2007-08-105072. Epub 2008 Jan 28.

16.

Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.

Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ.

J Biol Chem. 1997 Jun 27;272(26):16170-5.

17.

Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.

Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.

Blood. 1994 Nov 1;84(9):2912-8.

18.

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.

Senechal K, Halpern J, Sawyers CL.

J Biol Chem. 1996 Sep 20;271(38):23255-61.

19.

SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.

Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ, Qu CK.

Blood. 2007 Jan 15;109(2):778-85. Epub 2006 Sep 26.

20.

PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.

Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L.

Blood. 1996 Sep 1;88(5):1542-50.

Supplemental Content

Support Center